Publicaciones

1- López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R,  Díez J.
Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 2015;65:2449-2456
IF (2013): 15.343; Lugar: 1/125 Cardiac and cardiovascular systems; 1er decil
 

2- López B*, González A*, Querejeta R, Zubillaga E, Larman M, Díez J (*, both authors contributed equally). Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 2015;17:385-392.
IF (2013): 6.577; Lugar: 10/125 Cardiac and cardiovascular systems; 1er decil
 

3- Ravassa S, Kuznetsova T, Varo N, Thijs L, Delles C, Dominiczak A, Díez J, Staessen JA. Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. Int J Cardiol 2015;185:177-185.
IF (2013): 6.175; Lugar: 11/125 Cardiac and cardiovascular systems; 1er decil

 

4- Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CSP, Magpregioni AP, Tschöpe C, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014;35:2797-2815
IF (2013): 14.723; Lugar: 3/125 Cardiac and cardiovascular systems; 1er decil

 

5- López B*, González A*, Querejeta R, Larman M, Rábago G, Díez J J (*, both authors contributed equally). Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014;63:483-489.
IF (2013): 7.632; Lugar: 4/65 Peripheral vascular disease; 1er decil 

 

6- Beaumont J, López B, Hermida N, Schröen B, San José G, Heymans S, Valencia F, Gómez-Doblas JJ, de Teresa E, Díez J, González A. MicroRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin Sci 2014;126:497-506.
IF (2013): 5.629; Lugar: 14/122 Medicine, research and experimental; 1er cuartil
 

7- Hamdani N, Franssen C, Falcao-Pires I, Fontoura D, Leite S, Plettig S, López B, Ottenheijm CA, Becher MP, González A, Tschöpe C, Díez J,  Linke WA, Leite-Moreira AF, Paulus WJ. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 2013;6:1239-1249.
IF (2013): 5.945; Lugar: 14/125 Cardiac and cardiovascular systems; 1er cuartil
 

8- López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, Larman M, Tschöpe C, Díez J. Osteopontin-mediated myocardial fibrosis in heart failure. A role for lysyl oxidase? Cardiovasc Res 2013;99:111-120
IF (2013): 5.808; Lugar: 15/125 Cardiac and cardiovascular systems; 1er cuartil
 

9- Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Haydari B, Cirino AL, Lakdawala NK, Orav JE, González A, López B, Díez J, Jerosch-Herold M, Kwong RY. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging 2013;6:415-422
IF (2013): 6.752; Lugar: 9/125 Cardiac and cardiovascular systems; 1er decil

 

10- López B, Querejeta R, González A, Larman M, Díez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure. Potential role of lysyl oxidase. Hypertension 2012;60:677-683
IF (2012): 6.873; Lugar: 3/67 Peripheral vascular disease; 1er decil
 

11- González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833-1843.
IF (2011): 14.156; Lugar: 2/117 Cardiac and cardiovascular systems; 1er decil
 

12- Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, Barriales-Villa R, Castro-Beiras A, Díez J. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011;32:177-183
IF (2011): 10.478; Lugar: 3/117 Cardiac and cardiovascular systems; 1er decil
 

13- Ravassa S, García-Bolao I, Zudaire A, Macías A, Gavira JJ, Beaumont J, Arias T, Huerta A, Díez J. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res 2010;88:304-313.
IF (2010): 6.051; Lugar: 12/124 Cardiac & Cardiovascular Systems; 1er decil

 

14- González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010;55:1418-1424
IF (2010): 6.908; Lugar: 4/66 Peripheral vascular disease; 1er decil

 

15- Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-563
IF (2010): 53.484; Lugar: 1/151 Medicine, general and internal; 1er decil



"Exploramos nuevas estrategias terapéuticas dirigidas a corregir las alteraciones estructurales del miocardio en pacientes con insuficiencia cardíaca", Arantxa González, investigadora principal.

Contactar

Contacto:
Nerea Cano
Avda. Pío XII, 53
31008 Pamplona
España

(+34) 948 194 700 Ext. 3044
ncano@unav.es